^
    2ms
    Ambry Genetics Announces New Hereditary Cancer Test Menu at NSGC Annual Conference (Businesswire)
    "Ambry Genetics...announced enhancements to their portfolio of tests for the detection of genetic mutations associated with hereditary cancer. This new evidence-informed menu builds on the company’s 12-year history in hereditary cancer testing, to offer tests reflecting the latest scientific evidence and national consensus guidelines....Ambry will be featuring the enhancements to their hereditary cancer portfolio at the National Society of Genetic Counselors (NSGC) 2024 Annual Conference in New Orleans, Louisiana, from September 17 – 21. A symposium on 'Designing and Selecting Effective Panels for Maximized Clinical Utility' will be held by Ambry during the conference."
    Clinical
    |
    BRCANext® • CancerNext ® • ColoNext®
    8ms
    Ambry Genetics announces a collaboration with Tempus to advance paired germline and somatic testing services for medical oncologists (Ambry Genetics Press Release)
    "Ambry Genetics...and Tempus...announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services...As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext®️ and CancerNext-Expanded®️ assays...Tempus’ xG and xG+ germline assays are a part of Tempus' extensive portfolio of oncology-focused testing solutions that maximize biomarker detection and identify actionable variants linked to targeted therapy and clinical trial options."
    Licensing / partnership
    |
    CancerNext ® • CancerNext-Expanded® • Tempus xG